研究报告 |
|
|
|
|
抑癌基因PTEN转基因小鼠的构建及表型初步分析 |
李洪昌, 袁林, 张令强 |
军事医学科学院放射与辐射医学研究所 北京蛋白质组研究中心 蛋白质组学国家重点实验室 北京 100850 |
|
Construction of Transgenic Mice and Phenotypic Analysis of Tumor Suppressor PTEN |
LI Hong-chang, YUAN Lin, ZHANG Ling-qiang |
State Key Laboratory of Proteomics, Beijing Proteome Research Center, Beijing Institute of Radiation Medicine, Collaborative Innovation Center for Cancer Medicine, Beijing 100850, China |
[1] Maehama T, Dixon J E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem, 1998, 273(22):13375-13378.
[2] Hamada K, Sasaki T, Koni P A, et al. The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev,2005,19(17): 2054-2065.
[3] Hartmann W, Digon-Söntgerath B, Koch A, et al. Phosphatidylinositol 3-kinase/AKT signaling is activated in medulloblastoma cell prolifer action and is associated with reduced expression of PTEN. Clin Cancer Res,2006,12(10):3019-3027.
[4] Shen Y H, Zhang L, Gan Y, et al. Up-regulation of PTEN (phosphatase and tensin homolog deleted on chromosome ten) mediates p38 MAPK stress signal-induced inhibition of insulin signaling. A cross-talk between stress signaling and insulin signaling in resistin-treated human endothelial cells. J Biol Chem, 2006, 24; 281(12):7727-7736.
[5] Cairns P, Okami K, Halachmi S, et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res,1997,57(22):4997-5000.
[6] Feilotter H E, Nagai M A, Boag A H, et al. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene,1998,16(13):1743-1748.
[7] Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science,1997,275(5308):1943-1947.
[8] Risinger J I, Hayes A K, Berchuck A, et al. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res,1997,57(21):4736-4738.
[9] Steck PA, Pershouse M A, Jasser S A, et al. Identification of a candidate tumour suppressor gene, MMAC1 , at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet,1997,15(4):356-362.
[10] Yamada K M, Araki M. Tumor suppressor PTEN: Modulator of cell signaling, growth, migration and apoptosis. J Cell Sci,2001,114(Pt13):2375-2382.
[11] Liaw D, Marsh D J, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome.Nat Genet,1997,16(1):64-67.
[12] Marsh D J, Dahia P L, Zheng Z, et al. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet,1997,16(4):333-334.
[13] Di Cristofano A, Pesce B, Cordon-Cardo C, et al. Pten is essential for embryonic development and tumour suppression. Nat Genet,1998,19(4):348-355.
[14] Suzuki A, Pompa J L, Stambolic V, et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol,1998,8(21):1169-1178.
[15] Podsypanina K I, Ellenson L H, Nemes A, et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA,1999,96(4):1563-1568.
[16] Garcia-Cao I, Song M S, Hobbs R M, et al. Systemic elevation of PTEN induces a tumor-suppressive metabolic state.Cell,2012,149(1):49-62.
[17] Johnston L A, Prober D A, Edgar B A, et al. Drosophila myc regulates cellular growth during development.Cell,1999,98(6):779-790.
[18] Trumpp A, Refaeli Y, Oskarsson T, et al. c-Myc regulates mammalian body size by controlling cell number but not cell size.Nature,2001,414(6865):768-773.
[19] Deberardinis R J, Lum J J, Thompson C B. Phosphatidylinositol 3-kinase-dependent modulation of carnitine palmitoyltransferase 1A expression regulates lipid metabolism during hematopoietic cell growth.J Biol Chem,2006,281(49):37372-37380.
[20] King A, Gottlieb E. Glucose metabolism and programmed cell death: an evolutionary and mechanistic perspective. Curr Opin Cell Biol, 2009,21(6):885-893.
[21] Tennant D A, Duran R V, Boulahbel H, et al. Metabolic transformation in cancer. Carcinogenesis,2009,30(8):1269-1280.
[22] Alimonti A, Carracedo A, Clohessy J G, et al. Subtle variations in Pten dose determine cancer susceptibility.Nat Genet,2010,42(5):454-458.
[23] Carracedo A, Alimonti A, Pandolfi P P. PTEN level in tumor suppression: how much is too little.Cancer Res,2011,71(3):629-633.
[24] Trotman L C, Niki M, Dotan Z A, et al. Pten dose dictates cancer progression in the prostate.PLoS Biol,2003,1(3):385-396.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|